Loading...
Defines Aetna's medical necessity, experimental/investigational determinations, indications for diagnostic, therapeutic, surveillance (sequential/periodic) EGD and indications/technique recommendations for upper GI biopsy; includes extensive CPT/HCPCS/ICD-10 code lists for covered and not-covered indications. This is Part 1 of 4.
No material clinical or coverage changes in this update.
Scope: This Aetna Clinical Policy Bulletin (Number 0738) defines medical necessity, experimental/investigational determinations, and selection criteria for upper gastrointestinal endoscopy (EGD) and gastrointestinal biopsy—covering diagnostic, therapeutic, surveillance (sequential/periodic) uses, biopsy technique guidance (e.g., Seattle Protocol), and extensive CPT/HCPCS/ICD-10 code lists. Effective: 2007-11-09; Last review: 2023-10-04. High-level stance: multiple EGD indications are covered when criteria are met (diagnostic, therapeutic, surveillance, biopsy); a range of uses (including routine screening EGDs and many EndoFLIP applications) are designated experimental/investigational or not covered. This document is Part 1 of 4.
Medical Necessity - High-risk screening EGD (EGD/upper endoscopy)
Covered when ANY of the following are met:
ANY of the following
symptoms example: anemia, fatigue, pallor, red tongue, shortness of breath, tingling and numbness in hands and feet
Medical Necessity - Diagnostic EGD
Covered when ANY of the following are met:
ANY of the following
Medical Necessity - Therapeutic EGD
Covered when ANY of the following therapeutic interventions are performed:
ANY of the following
Medical Necessity - Sequential or periodic EGD (surveillance)
Covered when ANY of the following surveillance circumstances are met and intervals described:
ANY of the following
Medical Necessity - Biopsy indications and technique recommendations
Biopsy of the upper GI tract is medically necessary for the following indications and sampling guidance:
ANY of the following
Barrett's esophagus - Seattle Protocol
Medical Necessity - Endoscopic Submucosal Dissection (ESD) for Barrett's esophagus or early esophageal lesions
ESD is medically necessary when ANY of the following criteria are met:
ANY of the following
Experimental and Investigational - EGD and related technologies
Considered experimental and investigational (not established) for ANY of the following uses:
ANY of the following
Coverage — General clinical indications for EGD
Covered when ALL of the following general indications or specific diagnostic/treatment needs are met:
ALL of the following
Not generally indicated
EGD is generally not indicated when ANY of the following apply:
ANY of the following
Surveillance/Sequential EGD — Indications
Sequential or periodic EGD may be covered when surveillance for malignancy or specific high-risk conditions is indicated:
ANY of the following
Endoscopic biopsy coverage
Biopsy of the upper GI tract is covered when selection criteria/indications are met (e.g., suspected infection, neoplasm, gastritis, ulcers, celiac disease, IBD, suspected H. pylori, dysphagia, unexplained symptoms warranting tissue diagnosis).
ANY of the following
Procedural contraindications
Absolute and relative contraindications to EGD:
ANY of the following
Document medical indication and prior therapy
Document the specific clinical indication and prior treatments (e.g., prior noninvasive H. pylori testing and eradication status, and prior adequate trials of PPI or other therapy) in the medical record when requesting or performing EGD/biopsy to support medical necessity.
Document Barrett's esophagus biopsy sampling
When performing biopsies for Barrett's esophagus, record the number and spacing of four-quadrant biopsies per the Seattle Protocol (no dysplasia: every 2 cm; low-grade dysplasia: every 1–2 cm; high-grade dysplasia: every 1 cm) and document biopsy results in the chart.
Prior authorization may be required for therapeutic/complex procedures
Prior authorization may be required for complex or advanced therapeutic procedures (for example, ESD, POEM, advanced EUS-guided interventions); follow applicable payer prior authorization processes and verify requirements prior to scheduling.
H. pylori testing before endoscopy in patients <60 with dyspepsia
For patients younger than 60 with dyspepsia, document noninvasive H. pylori testing and treatment if positive, and persistent symptoms despite eradication, before proceeding with endoscopy; include H. pylori test type and eradication status in the record.
Indication documentation for biopsy and surveillance
Document the specific clinical indication when performing biopsy or surveillance EGD (examples: suspected neoplasm, active or recent GI bleeding, iron deficiency anemia with suspected upper source, Barrett's esophagus surveillance, severe caustic injury follow-up) so that procedure selection and frequency align with policy criteria.
Code selection per procedure type
Select and report procedure codes that match the service rendered; for example, use 0653T for transnasal EGD with biopsy and C9779 for endoscopic submucosal dissection when criteria are met. Ensure diagnosis codes on the claim support the medical necessity for the selected procedure.
Routine biopsies of normal-appearing esophagus not supported for dyspepsia-only indication
Routine biopsies of a normal-appearing esophagus or gastroesophageal junction for dyspepsia as the sole indication are not supported and may be denied; if such biopsies are performed, document a clear clinical justification tied to policy exceptions.
Consider selective pre-operative EGD before bariatric surgery
Selective pre-operative EGD before bariatric surgery should be based on symptoms, risk factors, and planned procedure type; document symptom status and rationale when obtaining pre-op EGD in asymptomatic or average-risk patients.
EndoFLIP is investigational/experimental in many applications
EndoFLIP (impedance planimetry) is considered investigational/experimental for many clinical applications listed in the policy (eg, achalasia, dysphagia, GERD, gastroparesis, prediction of outcome for Zenker's diverticulotomy, upper GI stenosis); document if used and recognize it may not establish coverage.
Use guideline-based indications for ESD vs EMR
When selecting endoscopic resection technique for Barrett's esophagus, document lesion size, morphology, suspicion for submucosal invasion, prior EMR findings (eg, positive margins), and other features to justify ESD versus EMR per guideline recommendations (EMR appropriate ≤1.0 cm; EMR or ESD 1.1–2.0 cm; ESD preferred >2.0 cm or for suspected submucosal invasion).
Document EndoFLIP procedural parameters
If EndoFLIP is used intra-procedurally, document the distension volume (eg, 30-ml or 40-ml as used in studies), pre- and post-intervention metrics (eg, distensibility index, narrowest CSA, balloon pressure), and presence of hiatal hernia to support interpretation of measurements.
Background summary: The policy reviews the role of standardized biopsy protocols and advanced tools in upper GI practice. The Seattle Protocol (four-quadrant biopsies at spacing adjusted by dysplasia status) and the Sydney protocol for H. pylori sampling are included as sampling guidance. Studies of EndoFLIP (impedance planimetry) report its capability to measure cross-sectional area, pressure, and distensibility intra-procedurally (used in POEM, tailored fundoplication, pyloric assessment, Zenker's diverticulum), with promising but preliminary results and calls for larger standardized studies.
Guideline and study points: major guideline and evidence excerpts note that ESD may be appropriate for Barrett's lesions with features suspicious for submucosal invasion, large/bulky nodularity, recurrent visible dysplasia, or lesions > 2.0 cm, while EMR is appropriate for smaller lesions (≤ 1.0 cm), and that ESD provides higher en bloc, R0 and curative rates but longer procedure time and higher perforation risk; a multicenter retrospective series showed markedly lower recurrence with ESD versus EMR (recurrence ~ 3.5% ESD vs 31.4% EMR).
Limitations: the policy emphasizes study limitations — small sample sizes, single-operator/center series, variability in EndoFLIP measurement volumes (30- vs 40-ml), confounding factors such as hiatal hernia, inconsistent case definitions (ERD vs NERD), and the need for standardized metrics and larger multicenter trials to validate EndoFLIP and some procedural innovations. Additionally, an RCT of fibrin glue after gastric ESD in high-risk patients found no reduction in overall bleeding (though acute bleeding was lower), illustrating mixed or limited high-quality evidence for some adjunctive interventions.
Appropriate trial of PPI therapy (for dyspepsia): a 2–4 week course of standard dose, once-daily proton pump inhibitor.
Appropriate therapy for reflux: an 8-week trial of standard dose once-daily PPI; dose may be increased to twice daily for partial responders.
Seattle Protocol (Barrett's esophagus biopsy): four-quadrant biopsies spaced by dysplasia status — without dysplasia every 2 cm; low-grade dysplasia every 1–2 cm; high-grade dysplasia every 1 cm.
Occult GI bleeding: initial presentation of positive FOBT and/or iron-deficiency anemia without visible fecal blood.
Obscure GI bleeding: bleeding of unknown origin that persists or recurs after negative initial primary endoscopy (colonoscopy and/or upper endoscopy).
EndoFLIP (FLIP, impedance planimetry): a catheter-mounted balloon device measuring cross-sectional area and intra-luminal pressure to calculate distensibility index and other luminal geometry metrics during endoscopy.
EGD / EGD (esophagogastroduodenoscopy): upper endoscopic examination of the esophagus, stomach, and duodenum.
DI (Distensibility index): distensibility index measured by FLIP (e.g., mm2/mmHg); nCSA: narrowest cross-sectional area measured by FLIP (mm2).
Policy number 0738 became effective.
Policy number 0738 last reviewed.
Planned next review date for policy number 0738.
Confirmation and specific histological diagnosis of radiologically demonstrated lesions
Infectious esophagitis
Metaplastic (chronic) atrophic gastritis